Visa Inc vs Viatris Inc — how do they compare? Visa Inc trades at $375 (market cap $704.20B), while Viatris Inc trades at $17.47 (market cap $20.03B). The key difference: Visa Inc is far larger — about 35.2× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.75%). Which is the better fit depends on your goals — on Pluang, investors hold Visa Inc for 115 Days and Viatris Inc for 57 Days on average.
| V | VTRS | |
|---|---|---|
Market Cap | $704.20B | $20.03B |
Volume | 6,405,857 | 14,109,977 |
Sector | Financials | Health |
52-Week High | $384.14 | $18.27 |
52-Week Low | $295.52 | $9.74 |
Typical Hold Time | 115 Days | 57 Days |
Enterprise Value | $714.78B | $32.15B |
Dividend Yield | 0.71% | 2.75% |
Signals from Pluang's Aura AI — not financial advice
Visa (V) trades at $372.10, up 0.39% with a bullish technical outlook. The stock shows strong fundamentals with 85% analyst buy ratings and a $422.24 consensus price target, representing 13.5% upside. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of $3.32 exceeding the $3.23 forecast. The company maintains exceptional profitability with 50.78% net margins and 61.79% ROE, while expanding AI-driven commerce initiatives through new partnerships and technology platforms.
Visa presents a compelling long-term investment case with dominant market position, consistent earnings growth, and strategic AI integration. Key risks include regulatory pressures, fintech competition, and stablecoin disruption potential. The current valuation at 31.67x P/E reflects premium pricing but is supported by strong growth prospects and defensive cash flow characteristics.
Viatris (VTRS) trades at $17.49, down 0.29% with a bullish technical signal and strong recent earnings beats. The company shows improving operational cash flow of $2.32B in 2025 and positive revenue growth trends, though profitability remains challenged with negative net margins. Recent developments include FDA approval for WAKIX in Japan and consistent dividend payments, supporting the bullish analyst consensus with a $22.17 price target representing 27% upside potential.
The outlook remains cautiously optimistic with strong cash generation supporting shareholder returns, but investors face risks from persistent negative profitability and high debt levels. The stock offers value appeal with reasonable P/S and P/B ratios, though the elevated P/E ratio reflects current earnings challenges that need resolution for sustained re-rating.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Visa Inc. operates a retail electronic payments network and manages global financial services. The Company also offers global commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.
Read more on V →Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →